Summary
1.24 -0.06(-4.62%)07/01/2024
Clearside Biomedical Inc (CLSD)
Clearside Biomedical Inc (CLSD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -4.62 | 13.76 | -3.88 | -21.52 | -3.88 | 9.73 | 19.23 | -82.90 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.24 | |
| Open | 1.29 | |
| High | 1.29 | |
| Low | 1.21 | |
| Volume | 72,858 | |
| Change | -0.06 | |
| Change % | -4.62 | |
| Avg Volume (20 Days) | 191,836 | |
| Volume/Avg Volume (20 Days) Ratio | 0.38 | |
| 52 Week Range | 0.65 - 2.12 | |
| Price vs 52 Week High | -41.51% | |
| Price vs 52 Week Low | 90.77% | |
| Range | -3.88 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 93 | |
| EBIDTA | -68,909,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 12.40 | |
| Book Value | 0.2990 | |
| Earnings Per Share | -0.4560 | |
| EPS Estimate Current Quarter | -0.0800 | |
| EPS Estimate Next Quarter | 0.1700 | |
| EPS Estimate Current Year | -0.1500 | |
| EPS Estimate Next Year | -0.4000 | |
| Diluted EPS (TTM) | -0.4560 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -6.7823 | |
| Return on asset (TTM) | -0.7381 | |
| Return on equity (TTM) | -1.9594 | |
| Revenue TTM | 3,899,000 | |
| Revenue per share TTM | 0.0700 | |
| Quarterly Revenue Growth (YOY) | -0.1040 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 7,894,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 9.7617 | |
| Revenue Enterprise Value | 38.4117 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 59,666,500 | |
| Shares Float | 46,283,319 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 11.57 | |
| Institutions (%) | 42.49 | |
06/27 07:05 EST - globenewswire.com
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced plans to host a virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET.
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced plans to host a virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET.
06/25 12:54 EST - benzinga.com
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc CLSD, a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc CLSD, a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.
06/12 07:05 EST - globenewswire.com
Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector ® - ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral presentations were delivered at the Clinical Trials at the Summit (CTS) Meeting on June 8, 2024 in Park City, Utah.
Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector ® - ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral presentations were delivered at the Clinical Trials at the Summit (CTS) Meeting on June 8, 2024 in Park City, Utah.
05/21 07:05 EST - globenewswire.com
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery -
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery -
05/09 21:14 EST - seekingalpha.com
Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Remy Bernarda - Investor Relations George Lasezkay - Chief Executive Officer Victor Chong - Chief Medical Officer Charlie Deignan - Chief Financial Officer Conference Call Participants Jon Wolleben - JMP Securities Operator Greetings, and welcome to the Clearside Biomedical First Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded.
Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Remy Bernarda - Investor Relations George Lasezkay - Chief Executive Officer Victor Chong - Chief Medical Officer Charlie Deignan - Chief Financial Officer Conference Call Participants Jon Wolleben - JMP Securities Operator Greetings, and welcome to the Clearside Biomedical First Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded.
05/09 19:56 EST - zacks.com
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.
05/09 16:05 EST - globenewswire.com
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga.
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga.
05/08 16:15 EST - globenewswire.com
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET in New York, NY.
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET in New York, NY.
04/30 07:05 EST - globenewswire.com
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
04/16 07:05 EST - globenewswire.com
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S.
04/02 07:05 EST - globenewswire.com
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the 23r d Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 3:00 p.m. ET.
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the 23r d Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 3:00 p.m. ET.
03/18 07:05 EST - globenewswire.com
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development
03/13 00:47 EST - seekingalpha.com
Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
03/12 16:05 EST - globenewswire.com
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector ® - - Strengthened Capital Position from Registered Direct Equity Offering and Recent SCS Microinjector License Agreement - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga.
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector ® - - Strengthened Capital Position from Registered Direct Equity Offering and Recent SCS Microinjector License Agreement - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga.
02/29 07:05 EST - globenewswire.com
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
02/25 13:37 EST - investorplace.com
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
02/07 08:00 EST - globenewswire.com
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale of 11,111,111 shares of common stock and accompanying warrant to purchase up to 11,111,111 shares of common stock in a registered direct offering. The offer price for one share of common stock and accompanying warrant to purchase one share of common stock will be $1.35. The warrants have an exercise price of $1.62 per share, will be exercisable six months from the issuance date and will have a term of five years from the initial exercise date. The offering is expected to close on or about February 9, 2024, subject to the satisfaction of customary closing conditions.
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale of 11,111,111 shares of common stock and accompanying warrant to purchase up to 11,111,111 shares of common stock in a registered direct offering. The offer price for one share of common stock and accompanying warrant to purchase one share of common stock will be $1.35. The warrants have an exercise price of $1.62 per share, will be exercisable six months from the issuance date and will have a term of five years from the initial exercise date. The offering is expected to close on or about February 9, 2024, subject to the satisfaction of customary closing conditions.
12/14 07:05 EST - globenewswire.com
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside's SCS Microinjector ® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD).
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside's SCS Microinjector ® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD).
11/13 19:18 EST - seekingalpha.com
Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference Call Participants Serge Belanger - Needham & Company Jon Wolleben - JMP Securities Jack Padovano - Stifel Yi Chen - H.C. Wainwright Operator Greetings, and welcome to the Clearside Biomedical Third Quarter 2023 Financial Results and Corporate Update Call.
Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference Call Participants Serge Belanger - Needham & Company Jon Wolleben - JMP Securities Jack Padovano - Stifel Yi Chen - H.C. Wainwright Operator Greetings, and welcome to the Clearside Biomedical Third Quarter 2023 Financial Results and Corporate Update Call.
11/13 16:05 EST - globenewswire.com
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside's Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor -
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside's Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor -